CRB 601
Alternative Names: CRB-601Latest Information Update: 13 Dec 2024
Price :
$50 *
At a glance
- Originator University of California at San Francisco
- Developer Corbus Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Integrin alphavbeta8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 09 Dec 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, and United Kingdom (IV) (NCT06603844)
- 19 Sep 2024 Corbus Pharmaceuticals plans a phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in the US and UK (IV) (NCT06603844)
- 09 Jan 2024 US FDA approves IND application for CRB-601 in Solid tumours